CAR T-cell products have the ability to completely change the treatment paradigm for hematologic malignancies.  These therapies are associated with life-threatening toxicities that require rapid intervention. Newly published consensus statements to better define and grade these toxicities should be incorporated into clinical practice.
Nurses play a critical role in the recognition and management of immune-related adverse events (irAEs). Education and training are needed to manage the needs of the growing patient population treated with these agents, particularly as our understanding of best practices for addressing complex toxicities evolves. The NCCN Guidelines provide helpful recommendations for assessing and managing irAEs in order to support optimal management of potentially life-threatening adverse events.
Nurses play a critical role in the recognition and management of immune-related adverse events (irAEs). Education and training are needed to manage the needs of the growing patient population treated with these agents, particularly as our understanding of best practices for addressing complex toxicities evolves. The NCCN Guidelines provide helpful recommendations for assessing and managing irAEs in order to support optimal management of potentially life-threatening adverse events.

Practical knowledge and skills are required to manage the needs of the growing patient population treated with ICIs, particularly as our understanding of best practices for addressing complex toxicities evolves.

Pages

Subscribe to RSS - Management of Immunotherapy-Related Toxicities